DK3186233T3 - Prober til billeddannelse af huntingtin-protein - Google Patents

Prober til billeddannelse af huntingtin-protein Download PDF

Info

Publication number
DK3186233T3
DK3186233T3 DK15836321.8T DK15836321T DK3186233T3 DK 3186233 T3 DK3186233 T3 DK 3186233T3 DK 15836321 T DK15836321 T DK 15836321T DK 3186233 T3 DK3186233 T3 DK 3186233T3
Authority
DK
Denmark
Prior art keywords
probs
imagination
huntingtin protein
huntingtin
protein
Prior art date
Application number
DK15836321.8T
Other languages
English (en)
Inventor
Celia Dominguez
John Wityak
Jonathan Bard
Alex Kiselyov
Christopher John Brown
Sebastien Rene Gabriel Galan
Michael Edward Prime
Paul Richard Giles
Thomas Martin Krülle
Daniel Clark-Frew
Peter David Johnson
Samuel Coe
Sarah Hayes
Elise Lucienne Paulette Gadouleau
Original Assignee
Chdi Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation Inc filed Critical Chdi Foundation Inc
Application granted granted Critical
Publication of DK3186233T3 publication Critical patent/DK3186233T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
    • A61B5/0035—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for acquisition of images from more than one imaging mode, e.g. combining MRI and optical tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK15836321.8T 2014-08-29 2015-08-28 Prober til billeddannelse af huntingtin-protein DK3186233T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462043603P 2014-08-29 2014-08-29
PCT/US2015/047407 WO2016033445A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Publications (1)

Publication Number Publication Date
DK3186233T3 true DK3186233T3 (da) 2021-11-22

Family

ID=55400648

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15836321.8T DK3186233T3 (da) 2014-08-29 2015-08-28 Prober til billeddannelse af huntingtin-protein

Country Status (20)

Country Link
US (3) US10479802B2 (da)
EP (2) EP4006016A3 (da)
JP (2) JP6817207B2 (da)
KR (2) KR102456946B1 (da)
CN (2) CN107108534B (da)
AU (1) AU2015308774B2 (da)
BR (1) BR112017004141B8 (da)
CA (1) CA2959501C (da)
DK (1) DK3186233T3 (da)
EA (1) EA035646B1 (da)
ES (1) ES2898965T3 (da)
HR (1) HRP20211778T1 (da)
HU (1) HUE056957T2 (da)
IL (1) IL250803B (da)
MX (2) MX2017002703A (da)
PL (1) PL3186233T3 (da)
PT (1) PT3186233T (da)
SG (1) SG11201701600QA (da)
SI (1) SI3186233T1 (da)
WO (1) WO2016033445A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10907197B2 (en) 2014-08-29 2021-02-02 Chdi Foundation, Inc. Probes for imaging huntingtin protein
CA2959531C (en) 2014-08-29 2023-01-10 Chdi Foundation, Inc. Probes for imaging huntingtin protein
PT3186233T (pt) * 2014-08-29 2021-12-02 Chdi Foundation Inc Sondas para imagem de proteína de huntingtina
SI3197277T1 (sl) 2014-08-29 2022-04-29 Chdi Foundation, Inc. Sonde za slikanje proteina huntingtina
SI3340796T1 (sl) 2015-08-28 2022-02-28 Chdi Foundation, Inc. Sonde za slikanje proteina huntingtina
KR102646115B1 (ko) 2016-03-11 2024-03-12 에이씨 이뮨 에스에이 진단 및 치료를 위한 바이사이클릭 화합물
CN107056723A (zh) * 2017-04-21 2017-08-18 云南大学 一种具有抑制血管内皮生长因子受体信号传导的化合物
US11512067B2 (en) 2017-09-14 2022-11-29 Daiichi Sankyo Company, Limited Compound having cyclic structure
BR112020020081A2 (pt) 2018-04-20 2021-01-05 Bayer Aktiengesellschaft Derivados de heterocicleno como agentes de controle de pragas
EP3802548A1 (en) 2018-06-08 2021-04-14 AC Immune SA Novel compounds for diagnosis
CN113874015B (zh) 2018-12-21 2024-05-24 细胞基因公司 Ripk2的噻吩并吡啶抑制剂
EP3931186A1 (en) 2019-02-25 2022-01-05 CHDI Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
CN111635400A (zh) 2019-03-02 2020-09-08 察略盛医药科技(上海)有限公司 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途
EP4077306A1 (en) * 2019-12-18 2022-10-26 CHDI Foundation, Inc. Compounds and probes for imaging huntingtin protein
JP2023525081A (ja) 2020-05-07 2023-06-14 エーシー・イミューン・エス・アー 診断のための新規化合物
WO2022031946A1 (en) * 2020-08-06 2022-02-10 Chdi Foundation, Inc. Heterobiaryl compounds and imaging agents for imaging huntingtin protein
WO2022216947A1 (en) * 2021-04-08 2022-10-13 Chdi Foundation, Inc. Isoindolinone compounds and imaging agents for imaging huntingtin protein
CA3216753A1 (en) 2021-04-27 2022-11-03 Longbin Liu Deuterated compounds and imaging agents for imaging huntingtin protein
KR20240035820A (ko) 2021-07-09 2024-03-18 플렉시움 인코포레이티드 Ikzf2를 조절하는 아릴 화합물 및 약학 조성물
WO2023083961A1 (en) 2021-11-10 2023-05-19 Ac Immune Sa Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis
WO2023083998A1 (en) 2021-11-10 2023-05-19 Ac Immune Sa Dihydropyrrolo[3,4c]-pyrazole derivatives and their use in diagnosis
AU2022385416A1 (en) 2021-11-10 2024-05-02 Ac Immune Sa 4h-imidazo[1,5-b]pyrazole derivatives for diagnosis

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985755A (en) 1972-06-02 1976-10-12 E. R. Squibb & Sons, Inc. Pyridine containing isothiocyanobenzoxazoles
US4198416A (en) 1976-09-30 1980-04-15 Meiji Seika Kaisha, Ltd. 5-Alkoxy-picolinic esters and anti-hypertensive composition containing 5-alkoxy-picolinic esters
DE2909754A1 (de) * 1979-03-13 1980-09-18 Thomae Gmbh Dr K Neue benzofuran- und benzothiophenderivate, deren herstellung und deren verwendung als arzneimittel
FR2524468B1 (fr) 1982-04-06 1985-10-18 Sandoz Sa Nouveaux derives condenses du thiophene, leur preparation et leur utilisation comme azurants optiques
JP2869561B2 (ja) * 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
US5041453A (en) * 1990-05-30 1991-08-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4
JP2600644B2 (ja) * 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
GB9203798D0 (en) * 1992-02-21 1992-04-08 Fujisawa Pharmaceutical Co Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
GB9317949D0 (en) * 1993-08-28 1993-10-13 Stevens Malcolm F G Benzothiazole compounds
JP3989569B2 (ja) * 1995-02-28 2007-10-10 イーライ リリー アンド カンパニー ベンゾチオフェン化合物、中間体、組成物および方法
JPH08325265A (ja) * 1995-05-29 1996-12-10 Fujisawa Pharmaceut Co Ltd チアゾリルベンゾフラン誘導体の製造方法、および該製造方法に用いられる化合物
DE69728581D1 (de) 1996-01-22 2004-05-13 Fujisawa Pharmaceutical Co Thiazolylbenzofuranderivate und ihre Verwendung als SRS-A- und Leukotrien-Antagonisten
JPH11171886A (ja) 1997-12-08 1999-06-29 Mitsui Chem Inc アミジンまたはグアニジンを側鎖にもつピロリルベンズイミダゾール誘導体
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
WO2003048140A1 (fr) * 2001-12-03 2003-06-12 Japan Tobacco Inc. Compose azole et utilisation medicinale de celui-ci
IL162243A0 (en) 2001-12-20 2005-11-20 Wyeth Corp Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
EP1624900A4 (en) 2003-05-20 2007-05-02 Univ California METHOD OF BINDING AGENTS AT BETA AMYLOID PLAQUE
AU2003304416A1 (en) 2003-08-13 2005-03-07 Bf Research Institute, Inc. Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
TW200616974A (en) 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
CN101384555A (zh) 2006-02-15 2009-03-11 塞诺菲-安万特股份有限公司 新的氨基醇取代的芳基二氢异喹啉酮类、其制备方法以及其作为药物的用途
EP2054060B1 (en) 2006-08-24 2014-04-02 Australian Nuclear Science & Technology Organisation Fluorinated ligands for targeting peripheral benzodiazepine receptors
JP5190893B2 (ja) * 2006-12-25 2013-04-24 国立大学法人東北大学 ベンゾキサゾール誘導体
WO2008134618A2 (en) * 2007-04-27 2008-11-06 The General Hospital Corporation Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders
KR101469275B1 (ko) 2007-06-01 2014-12-08 재단법인서울대학교산학협력재단 베타아밀로이드 침착의 영상화를 위한 헤테로사이클릭 인덴계열의 유도체 및 그의 방사성 동위원소 표지화합물
CA2700841A1 (en) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US20090123373A1 (en) * 2007-11-05 2009-05-14 Yanming Wang Amyloid-imaging agents
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
WO2009146388A1 (en) 2008-05-28 2009-12-03 The Trustees Of Columbia University In The City Of New York Voxel-based methods for assessing subjects using positron emission tomography
AU2009260526A1 (en) * 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted indoles
US8530483B2 (en) * 2008-05-30 2013-09-10 Merck Sharp & Dohme Corp. Substituted azabenzoxazoles
AU2009309027A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
GB0905664D0 (en) * 2009-04-02 2009-05-13 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
NZ595674A (en) 2009-04-02 2012-12-21 Ct Nac Investigaciones Oncologicas Cnio Imidazo[2,1-b][1,3,4]thiadiazole derivatives
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
JP2011168515A (ja) 2010-02-17 2011-09-01 Kowa Co エリスロポエチン産生促進作用を有する２−アリールベンゾオキサゾール化合物
WO2012007510A1 (en) * 2010-07-14 2012-01-19 Bayer Pharma Aktiengesellschaft Compounds for binding and imaging amyloid plaques and their use
AR084032A1 (es) * 2010-11-30 2013-04-17 Takeda Pharmaceutical Compuesto biciclico
CN102391260B (zh) 2011-09-29 2014-12-10 上海交通大学 3-甲酮-6-取代-苯并呋喃类化合物及其制备方法和用途
EP2847200B1 (en) 2012-04-26 2017-03-29 Bristol-Myers Squibb Company Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
US9370588B2 (en) 2013-01-04 2016-06-21 University Of Massachusetts Luciferin amides
GB201306248D0 (en) * 2013-04-05 2013-05-22 Ucl Business Plc Compounds and their uses
SG11201600108PA (en) 2013-07-17 2016-02-26 Otsuka Pharma Co Ltd Cyanotriazole compounds
SI3197277T1 (sl) 2014-08-29 2022-04-29 Chdi Foundation, Inc. Sonde za slikanje proteina huntingtina
CA2959531C (en) 2014-08-29 2023-01-10 Chdi Foundation, Inc. Probes for imaging huntingtin protein
US10907197B2 (en) 2014-08-29 2021-02-02 Chdi Foundation, Inc. Probes for imaging huntingtin protein
PT3186233T (pt) 2014-08-29 2021-12-02 Chdi Foundation Inc Sondas para imagem de proteína de huntingtina
SI3340796T1 (sl) 2015-08-28 2022-02-28 Chdi Foundation, Inc. Sonde za slikanje proteina huntingtina

Also Published As

Publication number Publication date
CN107108534B (zh) 2023-05-09
BR112017004141B1 (pt) 2022-04-19
SI3186233T1 (sl) 2022-04-29
CN116655618A (zh) 2023-08-29
AU2015308774B2 (en) 2020-03-19
KR20220148298A (ko) 2022-11-04
JP7126541B2 (ja) 2022-08-26
PT3186233T (pt) 2021-12-02
MX2021003311A (es) 2021-05-14
KR20170046173A (ko) 2017-04-28
PL3186233T3 (pl) 2022-02-28
HUE056957T2 (hu) 2022-04-28
SG11201701600QA (en) 2017-03-30
AU2015308774A8 (en) 2017-03-23
BR112017004141B8 (pt) 2022-08-02
IL250803A0 (en) 2017-04-30
WO2016033445A1 (en) 2016-03-03
JP2021059576A (ja) 2021-04-15
KR102456946B1 (ko) 2022-10-21
EP4006016A2 (en) 2022-06-01
JP6817207B2 (ja) 2021-01-20
EP3186233A4 (en) 2018-05-30
EP3186233B1 (en) 2021-08-25
ES2898965T3 (es) 2022-03-09
US20170283436A1 (en) 2017-10-05
CA2959501C (en) 2023-10-10
US10479802B2 (en) 2019-11-19
CN107108534A (zh) 2017-08-29
EP3186233B8 (en) 2021-09-29
US20230212190A1 (en) 2023-07-06
EA201790407A1 (ru) 2017-08-31
KR102586736B1 (ko) 2023-10-11
EP4006016A3 (en) 2022-11-16
HRP20211778T1 (hr) 2022-03-18
AU2015308774A1 (en) 2017-03-16
BR112017004141A2 (pt) 2017-12-12
EP3186233A1 (en) 2017-07-05
IL250803B (en) 2021-06-30
MX2017002703A (es) 2018-01-16
EA035646B1 (ru) 2020-07-21
US11059836B2 (en) 2021-07-13
US20200102328A1 (en) 2020-04-02
CA2959501A1 (en) 2016-03-03
JP2017528519A (ja) 2017-09-28

Similar Documents

Publication Publication Date Title
DK3186233T3 (da) Prober til billeddannelse af huntingtin-protein
DK3708668T3 (da) Kunstigt nukleinsyremolekyle til forbedret proteinudtrykkelse
DK3292137T3 (da) Proteiner specifikke for cd137
DK3197453T3 (da) Kimært protein
DK3183272T3 (da) Asymmetriske multispecifikke antistoffer
DK3126395T3 (da) Multispecifikke antistoffer
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3197277T3 (da) Prober til billeddannelse af huntingtin-protein
DK3182985T3 (da) Fibroinafledt proteinsammensætning
DK3201361T3 (da) Fremgangsmåder til kvantificering af cellefrit DNA
DK3186241T3 (da) Prober til billeddannelse af huntington-protein
DK3237432T3 (da) Proteinfremstilling
DK3348556T3 (da) Heteroarylamider som hæmmere af proteinaggregering
DK3099791T3 (da) Protein
DK3166611T3 (da) Fremgangsmåde til fremstilling af 4-alkoxy-3-hydroxypicolinsyrer
DK3340796T3 (da) Sonder til afbildning af huntingtin-protein
DK3164410T3 (da) Protein-indvinding
DK3099793T3 (da) Protein
DK3097076T3 (da) Hidtil ukendte cyp-eicosanoidderivater
FR3023290B1 (fr) Derives de flavaglines
DK3161136T3 (da) Fremgangsmåde til berigelse af mikrovesikler
FR3024647B1 (fr) Transat de puericulture
DK3149163T3 (da) Prohæmostatiske proteiner til behandling af blødning